Product logins

Find logins to all Clarivate products below.


$24,750.00   |  '

Dup15q Syndrome | Executive Insights | US/EU5/China | 2021

Executive Insights report on current medical practice, unmet need, and emerging treatments for Chromosome 15q Duplication Syndrome (Dup15q syndrome) in the U.S., Europe, and China.

Related Market Assessment Reports

Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
Report
Membranous Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Although it is one of the leading causes of nephrotic syndrome in…
Report
Migraine – Access & Reimbursement – Access & Reimbursement – Migraine Prophylaxis (US)
Preventive migraine care in the United States continues to evolve. Since 2018, CGRPtargeting mAbs (Aimovig, Emgality, Ajovy, Vyepti) and oral gepants (Nurtec ODT, Qulipta) have become established…